Development and validation of HPLC method for simultaneous quantitative determination of Azilsartan medoxomil potassium and Chlorthalidone in human plasma

Table of Contents

Chapter – 1: Introduction

Section- 1: General introduction

1 Bioanalytical techniques

2 Types of chromatography

3 Sample preparation techniques

4 Method validation

5 Bioavailability and bioequivalence

6 References

Section- 2: Introduction of Active Pharmaceutical Ingredients (API) used for present work by various instrumental method development and validation

1 Introduction of Azilsartan medoxomil

2 Introduction of Chlorthalidone

3 References:

Chapter-2: Development and validation of RP-HPLC methods for quantitative determination of some bioactive molecules in human plasma

Section-1: Development and validation of HPLC method for simultaneous quantitative determination of Azilsartan medoxomil potassium and Chlorthalidone in human plasma by HPLC

1 Aim of present work

2 Experimental

3 Method development

4 Results and discussion

5 Conclusion

Research Objectives and Thematic Focus

The primary objective of this work is to develop and validate a high-throughput, sensitive, and selective HPLC method for the simultaneous quantitative determination of Azilsartan medoxomil potassium and Chlorthalidone in human plasma to support clinical and pharmacokinetic studies.

• Development of a rugged HPLC method for simultaneous quantification.
• Optimization of sample extraction techniques using Solid Phase Extraction (SPE).
• Comprehensive validation of the analytical method according to USFDA guidelines.
• Evaluation of stability and matrix effects in human plasma samples.
• Application of the method for therapeutic drug monitoring and pharmacokinetic analysis.

Excerpt from the Book

Summary of Chapters

Chapter – 1: Introduction: Provides an overview of bioanalytical techniques, chromatography fundamentals, sample preparation methods, and the specific profiles of the Active Pharmaceutical Ingredients (APIs) under study.

Chapter-2: Development and validation of RP-HPLC methods for quantitative determination of some bioactive molecules in human plasma: Details the experimental design, optimization of the HPLC method, and validation results for the simultaneous determination of Azilsartan and Chlorthalidone.

Keywords

HPLC, Azilsartan medoxomil potassium, Chlorthalidone, Bioanalytical method validation, Human plasma, Solid Phase Extraction (SPE), Pharmacokinetics, Bioavailability, Bioequivalence, Chromatographic separation, Sensitivity, Selectivity, Stability.

Frequently Asked Questions

What is the primary goal of this research?

The study aims to develop and validate a sensitive and efficient HPLC method for the simultaneous quantification of Azilsartan medoxomil potassium and Chlorthalidone in human plasma.

Which analytical technique is primarily used?

The work utilizes Reversed Phase High Performance Liquid Chromatography (RP-HPLC) combined with Solid Phase Extraction (SPE).

What are the main therapeutic categories of the drugs studied?

Both drugs are primarily used as antihypertensive agents.

How is the sensitivity of the method ensured?

Sensitivity is optimized through careful selection of the chromatographic column, mobile phase composition, and efficient sample extraction techniques to reduce background noise.

Which sample preparation method was found most effective?

Solid Phase Extraction (SPE) was selected over Protein Precipitation (PPT) because it provided better recovery and cleaner samples for analysis.

How is method reliability demonstrated?

Reliability is established through comprehensive validation procedures, including testing for linearity, selectivity, accuracy, precision, and stability, following USFDA guidelines.

Why is SPE preferred over liquid-liquid extraction?

SPE is preferred as it excludes lengthy steps such as solvent evaporation and reconstitution, thereby saving time and reducing potential errors.

What is the significance of the plasma concentration-time profile?

It is used to assess pharmacokinetic parameters like Cmax, Tmax, and AUC, which are essential for determining the bioavailability and therapeutic effectiveness of the drug.

Does the method account for matrix effects?

Yes, matrix effect experiments were conducted to evaluate the influence of different sources of human plasma on the measurement of the analytes, demonstrating negligible endogenous interference.

How long are the samples stable?

Stability studies confirmed that the analytes remain stable in plasma for at least 35 days at -20°C and under bench-top conditions for at least 6 hours.